Bank of America Merrill Lynch Healthcare Conference

Bank of America Merrill Lynch Healthcare Conference Doug Williams, Ph.D. EVP, Research & Development May 13, 2015 1 Forward-Looking Statements This...
Author: Sophie Cobb
2 downloads 0 Views 709KB Size
Bank of America Merrill Lynch Healthcare Conference Doug Williams, Ph.D. EVP, Research & Development May 13, 2015

1

Forward-Looking Statements This presentation contains forward-looking statements, including statements about the prospects of our business and product portfolio, the potential and progress of our pipeline and business development activities, and anticipated clinical trials and data readouts. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our principal products; failure to compete effectively due to significant product competition in the markets for our products; failure to protect and enforce our data, intellectual property and other proprietary rights and the risks and uncertainties relating to intellectual property claims; difficulties in obtaining adequate coverage or changes in pricing or the availability of reimbursement for our products; the occurrence of adverse safety events, restrictions on use with our products or product liability claims; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products, including the risk that unexpected concerns may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies or may fail to approve or may delay approval of our drug candidates; results in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; our dependence on collaborators and other third parties for the development and commercialization of products and other aspects of our business, which are outside of our control; failure to manage our growth and execute our growth initiatives; problems with our manufacturing processes or capacity; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including exchange rate fluctuations; charges and other costs relating to our properties; currency fluctuations; fluctuations in our effective tax rate; the market, interest and credit risks associated with our portfolio of marketable securities; environmental risks; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC. These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements. Note regarding trademarks: ALPROLIX®, AVONEX®, ELOCTATE®, FUMADERMTM, PLEGRIDY®, RITUXAN®, TECFIDERA® and TYSABRI®, as used in this presentation, are trademarks or registered trademarks of Biogen or its subsidiaries. FAMPYRA® is a registered trademark of Acorda Therapeutics, Inc. GAZYVA® is a registered trademark of Genentech, Inc.

2

OUR GUIDING PRINCIPLES COMMITMENT TO PATIENTS

INNOVATION Neurology, Hematology & Immunology

COMMERCIAL EXCELLENCE

3

Record of Commercial Success Multiple Sclerosis

-- Ex US --

Anti-CD20

Hemophilia

4

Robust and Growing Business Revenues ($B)

$12.0

Non-GAAP Diluted EPS ($)

$16.0

+20% CAGR $9.7

$10.0

+28% CAGR 13.83

$14.0 $12.0

$8.0

$10.0

$6.9

$6.0 $4.7

$5.0

8.96

$8.0

$5.5

$6.0

$4.0

5.90

6.53

5.15

$4.0 $2.0

$2.0

$0.0

$0.0 2010

2011

2012

2013

2014

2010

2011

2012

2013

2014

Note: a reconciliation of our GAAP to non-GAAP EPS appears at the end of this presentation

5

Scientific Excellence

R&D Talent Novel Biology Multiple Therapeutic Modalities

6

Deep Pipeline PHASE I Late-stage

ZINBRYTA* GAZYVA*

Diffuse Large B-Cell Lymphoma

GAZYVA*

Indolent Non-Hodgkin’s Lymphoma (Refractory & Frontline)

TECFIDERA

Secondary Progressive Multiple Sclerosis

ISIS-SMNRx*

Spinal Muscular Atrophy

Anti-TWEAK

Alzheimer's Disease Optic Neuritis; Multiple Sclerosis Lupus Nephritis

BAN2401*

Alzheimer's Disease

Neublastin

Neuropathic Pain

CNV1014802 STX-100 TYSABRI E2609* Dapirolizumab pegol* BIIB061 ISIS-DMPKRx* Anti-BDCA2

FILED

Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Anti-LINGO

Early-stage

PHASE III

TYSABRI

Aducanumab (BIIB037)*†

BioSimilars

PHASE II

Trigeminal Neuralgia Idiopathic Pulmonary Fibrosis Acute Ischemic Stroke Alzheimer’s Disease SLE§ Multiple Sclerosis Myotonic Dystrophy SLE§

Biosimilar etanercept*

Multiple potential indications

Biosimilar infliximab*

Multiple potential indications * Collaboration programs

†Phase 3 planning underway

§Systematic Lupus Erthematosus

7

Interim Phase 1B Results of Aducanumab (BIIB037) Clinical Effect of Aducanumabb

0.05

Placebo 1 3 6 10 (n=34)(n=26)(n=27)(n=23)(n=27)

10 Placebo 1 3 6 (n=21)(n=21)(n=26) (N/A) (n=21)

MMSE

0.00 -0.05 -0.10 -0.15 -0.20

Placebo (n=37, 36, 23) Aducanumab 3 mg/kg (n=29, 29, 26) Aducanumab 10 mg/kg (n=30, 29, 25)

1

** ***

*** ***

-0.25 -0.30

Week 54

Week 26

***

Adjusted mean change from baseline (± SE)

Composite SUVR adjusted mean change from baseline (±SE)

Amyloid Plaque Reduction with Aducanumaba

**P

Suggest Documents